Sugi Predict

Sugi Predict / Compounds / SCHEMBL29937990

SCHEMBL29937990

SCHEMBL29937990

CCCC[C@@H](NC(=O)N[C@@H](Cc1ccccc1)C(=O)Nc1ccc([N+](=O)[O-])cc1)C(=O)N[C@@H](CCCCN)C(=O)OC

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ SSTR3 P32745 1/20 1.00
▸ PDF Q9HBH1 1/20 0.61
▸ CA12 O43570 1/20 0.46
▸ CA1 P00915 1/20 0.46
▸ CA2 P00918 1/20 0.46
▸ CA9 Q16790 1/20 0.46
▸ CALCRL Q16602 1/20 0.46
▸ BIRC2 Q13490 1/20 0.44
▸ CPB2 Q96IY4 1/20 0.43
▸ CTSL P07711 1/20 0.42
▸ ANPEP P15144 1/20 0.42
▸ POLB P06746 1/20 0.42
▸ ERAP2 Q6P179 1/20 0.42
▸ ERAP1 Q9NZ08 1/20 0.42
▸ FPR1 P21462 1/20 0.42
▸ FPR2 P25090 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10439499 0.83 SSTR3 (0.71) SSTR3PDFCALCRL
SCHEMBL8365389 0.83 SSTR3 (0.71) SSTR3PDFCALCRL
SCHEMBL8405097 0.83 SSTR3 (0.70) SSTR3PDFCALCRL
SCHEMBL18788630 0.79 SSTR3 (0.65) SSTR3PDFCALCRLCTSL
SCHEMBL18788631 0.79 SSTR3 (0.65) SSTR3PDFCALCRLCTSL
SCHEMBL10778136 0.78 SSTR3 (0.64) SSTR3PDFCA12CA1CA2
SCHEMBL1674876 0.78 SSTR3 (0.64) SSTR3PDF
SCHEMBL27182839 0.78 SSTR3 (0.64) SSTR3PDFCA12CA1CA2
SCHEMBL30055789 0.77 SSTR3 (0.61) SSTR3BIRC2CTSLANPEPERAP2
SCHEMBL27183243 0.77 SSTR3 (0.61) SSTR3CA12CA1CA2CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4380633-A2 STABILIZED COMPOSITIONS OF RADIONUCLIDES AND USES THEREOF Rayzebio, Inc. (US) 2024-06-12 — — EP claimed
CN-118103078-A Stabilized compositions of radionuclides and uses thereof 瑞择生物公司 2024-05-28 — — CN claimed
WO-2023191839-A9 STABILIZED COMPOSITIONS OF RADIONUCLIDES AND USES THEREOF RAYZEBIO, INC. (US) 2023-11-09 — — WO claimed
WO-2023191839-A2 STABILIZED COMPOSITIONS OF RADIONUCLIDES AND USES THEREOF RAYZEBIO, INC. (US) 2023-10-05 — — WO claimed
EP-4719497-A1 METHODS FOR TREATING SSTR POSITIVE CANCER Rayzebio, Inc. (US) 2026-04-08 — — EP disclosed
US-20250064996-A1 STABILIZED COMPOSITIONS OF RADIONUCLIDES AND USES THEREOF RAYZEBIO, INC. 2025-02-27 — — US disclosed
WO-2024248823-A1 METHODS FOR TREATING SSTR POSITIVE CANCER RAYZEBIO, INC. (US) 2024-12-05 — — WO disclosed
WO-2024249352-A1 METHODS FOR TREATING SSTR POSITIVE CANCER RAYZEBIO, INC. (US) 2024-12-05 — — WO disclosed
CN-118831183-A Stabilized compositions of radionuclides and uses thereof 瑞择生物公司 2024-10-25 — — CN disclosed
EP-4380633-A2 STABILIZED COMPOSITIONS OF RADIONUCLIDES AND USES THEREOF Rayzebio, Inc. (US) 2024-06-12 — — EP disclosed
CN-118103078-A Stabilized compositions of radionuclides and uses thereof 瑞择生物公司 2024-05-28 — — CN disclosed
US-20240123098-A1 STABILIZED COMPOSITIONS OF RADIONUCLIDES AND USES THEREOF RAYZEBIO, INC. 2024-04-18 — — US disclosed
US-11819556-B2 Stabilized compositions of radionuclides and uses thereof RAYZEBIO, INC. (US) 2023-11-21 — — US disclosed
WO-2023191839-A9 STABILIZED COMPOSITIONS OF RADIONUCLIDES AND USES THEREOF RAYZEBIO, INC. (US) 2023-11-09 — — WO disclosed
WO-2023191839-A2 STABILIZED COMPOSITIONS OF RADIONUCLIDES AND USES THEREOF RAYZEBIO, INC. (US) 2023-10-05 — — WO disclosed
US-20230293737-A1 STABILIZED COMPOSITIONS OF RADIONUCLIDES AND USES THEREOF RAYZEBIO, INC. 2023-09-21 — — US disclosed
US-11707540-B2 Stabilized compositions of radionuclides and uses thereof RAYZEBIO, INC. (US) 2023-07-25 — — US disclosed
US-20230144360-A1 STABILIZED COMPOSITIONS OF RADIONUCLIDES AND USES THEREOF RAYZEBIO, INC. 2023-05-11 — — US disclosed
US-11541134-B1 Stabilized compositions of radionuclides and uses thereof RAYZEBIO, INC. (US) 2023-01-03 — — US disclosed
US-11497822-B1 Stabilized compositions of radionuclides and uses thereof RAYZEBIO, INC. (US) 2022-11-15 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11497822-B1 Stabilized compositions of radionuclides and uses thereof TFRC, SLC39A14, EGFR SSTR3 137/4885PDF 724/4885CA12 135/4885
US-20230293737-A1 STABILIZED COMPOSITIONS OF RADIONUCLIDES AND USES THEREOF TFRC, SLC39A14, EGFR SSTR3 137/4885PDF 724/4885CA12 135/4885
US-11819556-B2 Stabilized compositions of radionuclides and uses thereof TFRC, SLC39A14, EGFR SSTR3 137/4885PDF 724/4885CA12 135/4885
US-20250064996-A1 STABILIZED COMPOSITIONS OF RADIONUCLIDES AND USES THEREOF TFRC, SLC39A14, EGFR SSTR3 137/4885PDF 724/4885CA12 135/4885
US-11541134-B1 Stabilized compositions of radionuclides and uses thereof TFRC, SLC39A14, EGFR SSTR3 137/4885PDF 724/4885CA12 135/4885
US-20230144360-A1 STABILIZED COMPOSITIONS OF RADIONUCLIDES AND USES THEREOF TFRC, SLC39A14, EGFR SSTR3 137/4885PDF 724/4885CA12 135/4885
US-20240123098-A1 STABILIZED COMPOSITIONS OF RADIONUCLIDES AND USES THEREOF TFRC, SLC39A14, EGFR SSTR3 137/4885PDF 724/4885CA12 135/4885
US-11707540-B2 Stabilized compositions of radionuclides and uses thereof TFRC, SLC39A14, EGFR SSTR3 137/4885PDF 724/4885CA12 135/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback